• Loading stock data…

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

[#item_full_content]

Print Friendly, PDF & Email
Spread the word